Trial Profile

Onyx ONE Clear: A Single Arm Trial With Resolute Onyx in ONE-Month DAPT for High-Bleeding Risk Patients Who Are Considered One-Month Clear (Onyx ONE Clear)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 05 Nov 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Zotarolimus (Primary) ; Antiplatelets
Indications Coronary artery disease
Focus Adverse reactions
Acronyms Onyx ONE Clear
Sponsors Medtronic

Most Recent Events

19 Sep 2022 Results presented at the Transcatheter Cardiovascular Therapeutics 2022
04 May 2021 Status changed from active, no longer recruiting to completed.
05 Jun 2020 According to an Medtronic media release, data have been submitted to the FDA with the intent of obtaining a one-month DAPT US Indication for Resolute Onyx DES.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com